Brand Name | Status | Last Update |
---|---|---|
cibinqo | New Drug Application | 2024-01-08 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
atopic dermatitis | EFO_0000274 | D003876 | L20 |
Expiration | Code | ||
---|---|---|---|
ABROCITINIB, CIBINQO, PFIZER | |||
2027-01-14 | NCE | ||
2026-02-09 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atopic dermatitis | D003876 | EFO_0000274 | L20 | 2 | 2 | 8 | 1 | 10 | 23 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Eczema | D004485 | HP_0000964 | L30.9 | — | — | 2 | — | 1 | 3 |
Skin diseases | D012871 | — | L00-L99 | — | 1 | 2 | — | — | 3 |
Immune system diseases | D007154 | — | D89.9 | — | — | 2 | — | — | 2 |
Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | 2 | — | — | 2 |
Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | 2 | — | — | 2 |
Genetic skin diseases | D012873 | — | — | — | — | 2 | — | — | 2 |
Eczematous skin diseases | D017443 | — | — | — | — | 2 | — | — | 2 |
Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | 2 | — | — | 2 |
Immediate hypersensitivity | D006969 | — | — | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | 1 | 2 |
Pruritus | D011537 | HP_0000989 | L29 | — | 1 | — | — | — | 1 |
Prurigo | D011536 | — | L28.2 | — | 1 | — | — | — | 1 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
Granuloma annulare | D016460 | — | L92.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 12 | — | — | — | — | 12 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Food hypersensitivity | D005512 | EFO_1001890 | — | 1 | — | — | — | — | 1 |
Drug common name | Abrocitinib |
INN | abrocitinib |
Description | Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1 |
PDB | — |
CAS-ID | 1622902-68-4 |
RxCUI | — |
ChEMBL ID | CHEMBL3655081 |
ChEBI ID | — |
PubChem CID | 78323835 |
DrugBank | DB14973 |
UNII ID | 73SM5SF3OR (ChemIDplus, GSRS) |